Omega Diagnostics Group PLC Change of preliminary results date (7778V)

TIDMODX

RNS Number : 7778V

Omega Diagnostics Group PLC

12 August 2022

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Change of preliminary results date and investor presentation

and update to CD4 sale

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition products, provides the following updates regarding the preliminary results for the year ended 31 March 2022, the investor presentation and the completion of sale of its CD4 Business, which was announced on the 3 August 2022.

Preliminary results and investor presentation update

The Company's auditors have requested further time to complete their work ahead of the release of the Company's preliminary results for the year ended 31 March 2022. The delay is due to a combination of the Company finalising the accounting adjustments in respect to the recent CD4 sale and the subsequent impact on completion of required audit procedures. Consequently, there will be delay to the release of the results, which will now be issued on Thursday 1 September 2022.

The investor presentation relating to the preliminary results which is to be held via the Investor Meet Company platform will now take place on Thursday 1 September 2022 at 4:30pm BST. The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group plc via:

https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor

The Company's Annual General Meeting date remains unchanged and will be held on 5 October 2022 at 1 Exchange Crescent, Conference Square, Edinburgh EH3 8UL at 11:00am.

Update on CD4 sale proceeds

Following the finalisation of the CD4 inventory valuation as at 31 July 2022, there has been an upward revision to the estimated sale proceeds from the originally stated aggregate cash consideration of up to GBP6.1m, before costs, to up to GBP6.3m. This results in an increase in the upfront cash payment due to the Company from GBP1,100,000 to GBP1,315,000, of which GBP463,000 has already been received. The balance is due to be received within the next 10 business days.

Contacts:

 
  Omega Diagnostics Group PLC                                        www.omegadx.com 
  Jag Grewal, Chief Executive Officer                                via Walbrook PR 
  Chris Lea, Chief Financial Officer 
 
  finnCap Ltd                                                     Tel: [phone] 
  Geoff Nash/Edward Whiley/George Dollemore 
   (Corporate Finance) 
  Alice Lane/ Harriet Ward (ECM) 
 
  Walbrook PR Limited                     Tel: [phone] or [e-mail] 
  Lianne Applegarth                                               Mob: [phone] 
  Sam Allen                                                       Mob: [phone] 
 
 
 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and is now focused on the health and nutrition sector.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORQFLFFLVLXBBK

(END) Dow Jones Newswires

August 12, 2022 02:00 ET (06:00 GMT)